Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1

Interventions

Trastuzumab 3Taxes 3Radiotherapy 3Paclitaxel 3Cyclophosphamide 3Epirubicin 2Doxorubicin 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1romidepsin 1pertuzumab 1pembrolizumab 1pegfilgrastim 1nintedanib 1neratinib 1grapiprant 1eribulin 1caficrestat 1bemcentinib 1Tamoxifen 1Razoxane 1Radiation 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammatory Breast Neoplasms × trastuzumab biosimilar HLX02 × Clear all
NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 15 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡